In this issue:
MACE in rheumatoid arthritis treated with JAK inhibitors
Secukinumab for giant cell arteritis after tocilizumab failure
Mepolizumab for eosinophilic granulomatosis with polyangiitis
Impact of conventional and targeted DMARDs on body weight
Switching from a TNF inhibitor in axial spondyloarthritis
Guselkumab in psoriatic arthritis with severe disease activity
Characterisation of super-responders with psoriatic arthritis
ASDAS to evaluate disease activity and response to treatment Tocilizumab for management of polymyalgia rheumatica
Dupilumab in IgG4-related disease
Please login below to download this issue (PDF)